tolbutamide has been researched along with rifampin in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (24.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (24.14) | 29.6817 |
| 2010's | 13 (44.83) | 24.3611 |
| 2020's | 2 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, T; Itoh, T; Kato, Y; Kusuhara, H; Meier, PJ; Shitara, Y; Sugiyama, D; Sugiyama, Y | 1 |
| Ekins, S; Harwood, HJ; Hoover, DJ; Lawton, MP; Mankowski, DC; Treadway, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Gugler, R | 1 |
| Christensen, LK; Hansen, JM | 1 |
| Breimer, DD; Richter, E; Zilly, W | 2 |
| Iisalo, E; Pihlajamäki, K; Syvälahti, E | 1 |
| Iisalo, EJ; Pihlajamäki, KK; Syvälahti, EK | 1 |
| Bopp, E; Bürkl, B; Richter, E; Zilly, W | 1 |
| Adams, M; Ahdieh, H; Gammaitoni, AR; Pieniaszek, HJ | 1 |
| Ackermans, MT; Camus, S; Chamuleau, RA; Elferink, RP; Hoekstra, R; Kulik, W; Nibourg, GA; Plomer, G; Seppen, J; van der Hoeven, TV; van Gulik, TM | 1 |
| Abdulrasool, LI; Endres, CJ; Lee, A; Mayor, JG; Rustia, EL; Sun, H; Topletz-Erickson, A; Walker, L | 1 |
| Aarnoutse, RE; Boeree, MJ; Coenen, MJH; Colbers, A; Dawson, R; Diacon, AH; Fuhr, U; Jager, Vd; Narunsky, K; Padayachee, SD; Phillips, PPJ; Stemkens, R; Svensson, EM; Te Brake, LHM; van Beek, SW | 1 |
2 review(s) available for tolbutamide and rifampin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug interactions with oral sulphonylurea hypoglycaemic drugs.
Topics: Allopurinol; Analgesics; Anticoagulants; Chloramphenicol; Chlorpropamide; Disulfiram; Drug Interactions; Ethanol; Glyburide; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Kinetics; Monoamine Oxidase Inhibitors; Novobiocin; Phenylbutazone; Phenytoin; Probenecid; Propranolol; Rifampin; Sulfonamides; Sulfonylurea Compounds; Tolbutamide | 1977 |
1 trial(s) available for tolbutamide and rifampin
| Article | Year |
|---|---|
Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways.
Topics: Adolescent; Adult; Analgesics, Opioid; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Delayed-Action Preparations; Drug Interactions; Erythromycin; Female; Humans; Male; Midazolam; Middle Aged; Naltrexone; Oxymorphone; Rifampin; Tolbutamide | 2005 |
26 other study(ies) available for tolbutamide and rifampin
| Article | Year |
|---|---|
Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport.
Topics: Algorithms; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antitubercular; Antimalarials; Biological Transport, Active; Digoxin; Enzyme Inhibitors; Estradiol; Ibuprofen; LLC-PK1 Cells; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Organic Cation Transport Proteins; Quinidine; Quinine; Rats; Rifampin; Swine | 2002 |
Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors.
Topics: Amides; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Humans; Indoles; Models, Molecular; Oxidoreductases; Quantitative Structure-Activity Relationship; Sterol 14-Demethylase | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
[Drug interactions in therapy using coumarin derivatives].
Topics: Allopurinol; Anti-Inflammatory Agents; Barbiturates; Biological Availability; Cholestyramine Resin; Coumarins; Drug Interactions; Humans; Metronidazole; Phenylbutazone; Rifampin; Sulfonamides; Tolbutamide | 1979 |
Stimulation of drug metabolism by rifampicin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance.
Topics: Adult; Aged; Cholestasis; Female; Hexobarbital; Humans; Kinetics; Liver Cirrhosis; Male; Metabolic Clearance Rate; Middle Aged; Rifampin; Stimulation, Chemical; Time Factors; Tolbutamide | 1977 |
Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance.
Topics: Adult; Creatine; Half-Life; Hexobarbital; Humans; Kinetics; Liver Function Tests; Male; Metabolic Clearance Rate; Models, Biological; Rifampin; Tolbutamide | 1975 |
Effect of tuberculostatic agents on the response of serum growth hormone and immunoreactive insulin to intravenous tolbutamide, and on the half-life of tolbutamide.
Topics: Adult; Aged; Antitubercular Agents; Blood Glucose; Growth Hormone; Half-Life; Humans; Insulin; Male; Middle Aged; Rifampin; Tolbutamide | 1976 |
Letter: Rifampicin and drug metabolism.
Topics: Aminosalicylic Acids; Contraceptives, Oral; Ethambutol; Female; Growth Hormone; Half-Life; Humans; Isoniazid; Liver; Rifampin; Streptomycin; Tolbutamide | 1974 |
[Effect of rifampicin on the pharmacokinetics of tolbutamide in healthy subjects].
Topics: Adult; Drug Synergism; Humans; Kinetics; Liver; Rifampin; Tolbutamide | 1974 |
Phase 1 and phase 2 drug metabolism and bile acid production of HepaRG cells in a bioartificial liver in absence of dimethyl sulfoxide.
Topics: Aryl Hydrocarbon Hydroxylases; Bile Acids and Salts; Bilirubin; Bioreactors; Biotransformation; Cell Culture Techniques; Cell Line; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Dimethyl Sulfoxide; Glucuronosyltransferase; Hepatocytes; Humans; Hydroxylation; Isoenzymes; Kinetics; Liver, Artificial; Metabolic Detoxication, Phase I; Metabolic Detoxication, Phase II; Rifampin; Substrate Specificity; Testosterone; Tolbutamide | 2013 |
Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers.
Topics: Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Digoxin; Drug Interactions; Gemfibrozil; Healthy Volunteers; Humans; Itraconazole; Midazolam; Oxazoles; Pyridines; Quinazolines; Rifampin; Tolbutamide | 2022 |
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
Topics: Adult; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Humans; Midazolam; Omeprazole; Rifampin; Tolbutamide; Tuberculosis, Pulmonary | 2023 |